RE:RE:RE:RE:Failure, again."In general 10 % of candidates get to market and this will probably be in 2035 - Gagnon says in 7 years - and also none of them might get there"
Avalyn raised C$80 million going into its Phase I clinical trial. It just raised C$240 million going into its late stage trials. CZO's drug can work for fibrosis outside the lungs too and PGX-YBG ca be used to deliver other drugs or bioactives for other diseases. CZO appears to be conducting a short toxicology study in preperation of a Phase I trial filing. It uses yeast beta glucan which is already sold to humans and is believed safe; however CZO is administering it to the lungs, etc.
The scientist at McMaster who helped Avalyn get to trials said this about CZO's product.
“Until now, we have had very limited treatment options for fibrotic lung disease since approved medications can only slow down the progression of the disease. We are very encouraged by the results from this study showing that PGX-YBG has the ability of reprogramming macrophages to prevent fibrogenesis in mice. If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a respected Pulmonologist and Professor of Medicine at McMaster University." news release